Abstract
This review describes the clinical status (based on available information) of experimental drugs that inhibit enzymes called proteases, or more precisely a sub-class of proteases called peptidases that catalyse the hydrolysis of polypeptide main chain amide bonds. These peptidases are classified by the key catalytic residue in the active site of the enzyme that effects hydrolysis, namely aspartic, serine, cysteine, metallo or threonine proteases. In this review we show structures for 108 inhibitors of these enzymes and update the clinical disposition of over 100 inhibitors that have been considered worthy enough by pharmaceutical, biotechnology or academic researchers and their financial backers to be trialed in humans as prospective medicines. We outline some of their chemical and pharmacological characteristics and compare the current status of protease inhibitors in the clinic with what was observed about 5 years ago (Leung et al, J. Med. Chem. 2000, 43, 305-341). We assess the progress of protease inhibitors into man, predict their futures, and outline some of the hurdles that have been overcome and that still remain for this promising class of new therapeutic agents.
Keywords: protease, proteinase, peptidase, inhibitor, review, clinic
Medicinal Chemistry
Title: Protease Inhibitors in the Clinic
Volume: 1 Issue: 1
Author(s): Giovanni Abbenante and David P. Fairlie
Affiliation:
Keywords: protease, proteinase, peptidase, inhibitor, review, clinic
Abstract: This review describes the clinical status (based on available information) of experimental drugs that inhibit enzymes called proteases, or more precisely a sub-class of proteases called peptidases that catalyse the hydrolysis of polypeptide main chain amide bonds. These peptidases are classified by the key catalytic residue in the active site of the enzyme that effects hydrolysis, namely aspartic, serine, cysteine, metallo or threonine proteases. In this review we show structures for 108 inhibitors of these enzymes and update the clinical disposition of over 100 inhibitors that have been considered worthy enough by pharmaceutical, biotechnology or academic researchers and their financial backers to be trialed in humans as prospective medicines. We outline some of their chemical and pharmacological characteristics and compare the current status of protease inhibitors in the clinic with what was observed about 5 years ago (Leung et al, J. Med. Chem. 2000, 43, 305-341). We assess the progress of protease inhibitors into man, predict their futures, and outline some of the hurdles that have been overcome and that still remain for this promising class of new therapeutic agents.
Export Options
About this article
Cite this article as:
Abbenante Giovanni and Fairlie P. David, Protease Inhibitors in the Clinic, Medicinal Chemistry 2005; 1 (1) . https://dx.doi.org/10.2174/1573406053402569
DOI https://dx.doi.org/10.2174/1573406053402569 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Influence of Ultrasound Mediated Transdermal Delivery of Losartan Potassium
Drug Delivery Letters Tapping into Mitochondria to Find Novel Targets for Diabetes Complications
Current Drug Targets Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology Novel Peptides: An Alternative Approach for the Treatment of Diabetes Mellitus
Current Drug Therapy Non-Respiratory Manifestations of COVID-19 and Pathophysiological Evidences
New Emirates Medical Journal Mitochondrial Dysfunction and Alzheimers Disease
Current Alzheimer Research Editorial [ Hot Topic: Cancer Therapy-Related Cardiotoxicity (Guest Editor: Maysa Abu-Khalaf and Feras Bader)]
Current Cardiology Reviews A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer s Disease, in Healthy Subjects and Patients
Current Clinical Pharmacology Extrasynaptic GABA<sub>A</sub> Receptors in the Brainstem and Spinal Cord: Structure and Function
Current Pharmaceutical Design C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design SALL4: Engine of Cell Stemness
Current Gene Therapy Assessment of Selective Homing and Contribution to Vessel Formation of Cryopreserved Peripherally Injected Bone Marrow Mononuclear Cells Following Experimental Myocardial Damage
Cardiovascular & Hematological Disorders-Drug Targets Mini Review: Recent Advances in the Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Current Pharmaceutical Design Veno-Arterial Extracorporeal Membrane Oxygenation in the Adult: A Bridge to the State of the Art
Current Cardiology Reviews Inflamm-Aging, Cytokines and Aging: State of the Art, New Hypotheses on the Role of Mitochondria and New Perspectives from Systems Biology
Current Pharmaceutical Design Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Nephrotoxicity of Bisphenol A (BPA) -An Updated Review
Current Molecular Pharmacology Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design Phytochemical Characterization of Prickly Pear (Opuntia spp.) and of its Nutritional and Functional Properties: A Review
Current Nutrition & Food Science